U.S. and global drug manufacturers invested in Russia’s sizable pharmaceutical industry contend international humanitarian law requires they continue manufacturing and selling their products there, even while condemning the Ukraine invasion. Not everyone agrees.
Montanans engage in plenty of spirited political disagreements. But debates about covid-19, public health, and personal liberties have reached a fever pitch, tugging at tightknit towns and making some residents wonder how their communities will survive.
The agency’s updated recommendations lower the level of covid risk for most of the country and therefore the need to mask. But some experts question the strategy.
The University of California-Davis has spent close to $50 million preventing the spread of covid on campus — and among residents and workers in the adjacent city of Davis. By most accounts, this town-gown experiment has paid off nicely.
Doctors and scientists are debating whether a little-known measure in covid testing should be used to distinguish who is infectious from who isn’t. The NFL adopted the practice, but laboratory professionals caution against its use.
KHN Senior Correspondent Samantha Young joined California Health and Human Services Secretary Mark Ghaly for an engaging conversation about how California moves forward in an environment in which covid persists, but at more manageable levels.
Medicare has proposed limiting coverage of Aduhelm, the costly new drug to treat Alzheimer’s disease, and several prominent groups representing patients and their families are pressing the program to make it more widely available. But among individuals facing the disease, the outlook is more nuanced.
The on-off nature of the pandemic “has led to a lot of the confusion and grumpiness,” says one expert. Another compares it to the exhaustion of the American public when hearing body counts during the Vietnam War.
Kennedy Stonum, a 17-year-old high school junior, resisted getting vaccinated against covid-19, as did 20-year-old Tyler Gilreath, whose mother had nagged him for months to get the shots. Both died.
Spun off from the ailing but not-quite-dead Build Back Better legislation, a popular proposal to cap out-of-pocket insulin costs at $35 a month faces tough political realities that could kill it.
